Surface Oncology, Inc. (SURF)
Chart Events
Performance Outlook
| Previous Close | 1.7700 |
| Open | 1.7600 |
| Bid | 1.7400 x 800 |
| Ask | 1.7500 x 1100 |
| Day's Range | 1.7200 - 1.7600 |
| 52 Week Range | 1.3700 - 8.3800 |
| Volume | |
| Avg. Volume | 789,419 |
| Market Cap | 100.973M |
| Beta (5Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2330 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.10 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SURF
Related Research
- Surface Oncology, Inc.Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.RatingFair ValueEconomic Moat8 days agoArgus Research
- Simply Wall St.
Analysts Have Just Cut Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Estimates By 11%
The analysts covering Surface Oncology, Inc. ( NASDAQ:SURF ) delivered a dose of negativity to shareholders today, by...
- Simply Wall St.
How Much Of Surface Oncology, Inc. (NASDAQ:SURF) Do Institutions Own?
If you want to know who really controls Surface Oncology, Inc. ( NASDAQ:SURF ), then you'll have to look at the makeup...
- GlobeNewswire
Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022
– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization – – Interim SRF617 clinical data anticipated in the fourth quarter of 2022 – – Multiple clinical readouts anticipated in 1H 2023, including initial safety and efficacy data from SRF388 open-label, lead-in to randomized Phase 2 study in first-line hepatocellular carcinoma (HCC) – – Cash sufficient to fund operations in
